Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437760 | 1.00 | MAOA (0.43) | MAOAMAOBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3589461 | 0.89 | TYMS (0.41) | ALDH1A1MEN1KMT2AMAPK1TYMS | |
| SCHEMBL4441921 | 0.89 | TYMS (0.41) | ALDH1A1MEN1KMT2AMAPK1TYMS | |
| SCHEMBL2351853 | 0.89 | TYMS (0.41) | ALDH1A1MEN1KMT2AMAPK1TYMS | |
| SCHEMBL20835488 | 0.88 | TYMS (0.48) | MAOAMAOBMEN1KMT2ATSHR | |
| SCHEMBL20835437 | 0.87 | L3MBTL1 (0.41) | ALDH1A1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL2581106 | 0.87 | TP53 (0.44) | ALDH1A1MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL2346142 | 0.87 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ATSHRTYMS | |
| SCHEMBL20835401 | 0.84 | TYMS (0.35) | ALDH1A1LMNASMN1; SMN2NPSR1GAA | |
| SCHEMBL20835374 | 0.84 | TSHR (0.40) | ALDH1A1LMNASMN1; SMN2NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125829-B1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8008293-B2 | Bicyclic oxomorpholine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207900-A1 | TWO CYCLIC OXOMORPHORIN DERIVATIVES | OPRM1, OPRK1, OPRD1 | MAOA 887/4885MAOB 806/4885ALDH1A1 2062/4885 |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | MAOA 1375/4885MAOB 1849/4885ALDH1A1 869/4885 |
| US-20100113773-A1 | BICYCLIC OXOMORPHOLINE DERIVATIVE | OPRM1, OPRK1, OPRD1 | MAOA 375/4885MAOB 344/4885ALDH1A1 1360/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | MAOA 921/4885MAOB 692/4885ALDH1A1 674/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | MAOA 1375/4885MAOB 1849/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.